Navan Technologies, Inc., a San Francisco, CA-based biotechnology company, closed a seed funding round of undisclosed amount.
Backers included Amgen Ventures, High-Tech Gründerfonds (HTGF), Hemi Ventures, and other institutional and private investors.
Led by Michael J. Nowak, Ph.D., President and Chief Executive Officer, Navan Technologies enables the development of next generation cell and gene therapies through its novel, non-viral NanoStraw platform. Based on technology exclusively licensed from Stanford University, The company is also supported by a National Science Foundation STTR Phase II award and is a resident company at JLABS @ SSF located at Oyster Point in South San Francisco, CA.
The company intends to use the funds to further develop the NanoStraw platform development, scale-up production capabilities, and facilitate strategic collaborations and partnerships to accelerate the development of therapeutics programs.